Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

🧬 Blocking TGF-β, Boosting Function, Sotatercept's Early Advantage inPAH

5:08
 
Share
 

Manage episode 511985030 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🚨 Just out in NEJM! In the Phase 3 HYPERION trial, adding sotatercept early in pulmonary arterial hypertension (PAH) slashed clinical worsening risk by 76% vs placebo (HR 0.24, P<0.001) 💉🫁

💡 Benefits appeared after just 3 doses, with improved 6-min walk, NT-proBNP, and risk scores. Most AEs were mild (epistaxis, telangiectasia).

📊 A game-changer in early PAH therapy. NNT = 5 over 12 months.

🔗 #Cardiology #PulmonaryHypertension #Sotatercept #NEJM #PrecisionMedicine #ClinicalTrials #RightHeart #TGFb #REVEAL #COMPERA

  continue reading

753 episodes

Artwork
iconShare
 
Manage episode 511985030 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🚨 Just out in NEJM! In the Phase 3 HYPERION trial, adding sotatercept early in pulmonary arterial hypertension (PAH) slashed clinical worsening risk by 76% vs placebo (HR 0.24, P<0.001) 💉🫁

💡 Benefits appeared after just 3 doses, with improved 6-min walk, NT-proBNP, and risk scores. Most AEs were mild (epistaxis, telangiectasia).

📊 A game-changer in early PAH therapy. NNT = 5 over 12 months.

🔗 #Cardiology #PulmonaryHypertension #Sotatercept #NEJM #PrecisionMedicine #ClinicalTrials #RightHeart #TGFb #REVEAL #COMPERA

  continue reading

753 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play